Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)

v3.24.1.1.u2
Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Basic and diluted numerator:        
Net loss from continuing operations $ (2,635) $ (6,279) $ (12,197) $ (24,379)
Net loss from discontinued operations (537) (1,015) (4,932) (34,598)
Net loss $ (3,172) $ (7,294) $ (17,129) $ (58,977)
Basic and diluted denominator:        
Weighted-average common shares outstanding - basic 3,713 659 2,247 530
Weighted-average common shares outstanding - diluted 3,713 659 2,247 530
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (0.71) $ (9.53) $ (5.43) $ (46.00)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (0.71) (9.53) (5.43) (46.00)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (0.14) (1.54) (2.19) (65.28)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (0.14) (1.54) (2.19) (65.28)
Per share amount basic (0.85) (11.07) (7.62) (111.28)
Per share amount diluted $ (0.85) $ (11.07) $ (7.62) $ (111.28)